stoxline Quote Chart Rank Option Currency Glossary
  
Standard BioTools Inc. (LAB)
1.4  -0.01 (-0.71%)    02-18 16:00
Open: 1.44
High: 1.51
Volume: 1,849,779
  
Pre. Close: 1.41
Low: 1.37
Market Cap: 521(M)
Technical analysis
2025-02-18 4:45:05 PM
Short term     
Mid term     
Targets 6-month :  2.06 1-year :  2.49
Resists First :  1.76 Second :  2.14
Pivot price 1.43
Supports First :  1.16 Second :  0.97
MAs MA(5) :  1.36 MA(20) :  1.49
MA(100) :  1.78 MA(250) :  2.07
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  41.4 D(3) :  36.7
RSI RSI(14): 40.8
52-week High :  3.03 Low :  1.16
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ LAB ] has closed above bottom band by 41.3%. Bollinger Bands are 28.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.51 - 1.52 1.52 - 1.53
Low: 1.35 - 1.36 1.36 - 1.37
Close: 1.39 - 1.4 1.4 - 1.41
Company Description

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Headline News

Wed, 19 Feb 2025
Standard BioTools (LAB) Expected to Announce Earnings on Wednesday - MarketBeat

Tue, 18 Feb 2025
Standard BioTools (NASDAQ:LAB) Stock Price Up 7.1% - Here's What Happened - MarketBeat

Thu, 13 Feb 2025
Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025 - GlobeNewswire

Sun, 09 Feb 2025
Is Standard BioTools (NASDAQ:LAB) Using Debt Sensibly? - Simply Wall St

Mon, 13 Jan 2025
Standard BioTools stock soars on Q4 revenue beat - Investing.com

Mon, 13 Jan 2025
In the wake of Standard BioTools Inc.'s (NASDAQ:LAB) latest US$52m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 372 (M)
Shares Float 49 (M)
Held by Insiders 1.8 (%)
Held by Institutions 73.3 (%)
Shares Short 12,850 (K)
Shares Short P.Month 13,520 (K)
Stock Financials
EPS -0.69
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.23
Profit Margin -80 %
Operating Margin -29.5 %
Return on Assets (ttm) -14.7 %
Return on Equity (ttm) -37.3 %
Qtrly Rev. Growth -14.2 %
Gross Profit (p.s.) 0.2
Sales Per Share 0.41
EBITDA (p.s.) -0.31
Qtrly Earnings Growth 0 %
Operating Cash Flow -143 (M)
Levered Free Cash Flow -66 (M)
Stock Valuations
PE Ratio -2.03
PEG Ratio 0
Price to Book value 1.13
Price to Sales 3.34
Price to Cash Flow -3.64
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android